• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

毛细血管密度作为贝伐单抗治疗转移性结直肠癌疗效的早期生物标志物无价值：一项前瞻性临床试验

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.

作者信息

Fumet Jean-David, Bertaut Aurélie, Bengrine Leila, Lapierre Patricia, Vincent Julie, Ghiringhelli François, Falvo Nicolas

机构信息

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France.

出版信息

Oncotarget. 2017 Dec 1;9(16):12599-12608. doi: 10.18632/oncotarget.22822. eCollection 2018 Feb 27.

DOI:10.18632/oncotarget.22822
PMID:29560093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5849157/
Abstract

BACKGROUND

Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density. We evaluated the link between decreased capillary density and the response to bevacizumab-based chemotherapy.

RESULTS

Overall, 43 patients with metastatic colorectal cancer treated with first-line bevacizumab-based chemotherapy were enrolled. At Day 90, progressive disease was observed in 12 patients (27.9%). All patients presented decreased capillary density. ROC analysis at different time points and capillary density variation showed a poor diagnostic performance regarding response at Day 90.

MATERIALS AND METHODS

From 2013 to 2015, patients with metastatic colorectal cancer treated in our French cancer care center and eligible for bevacizumab with chemotherapy were enrolled in a prospective single-center study. Capillary density was assessed using capillaroscopy at Day 1, Day 15 and Day 30. Response to bevacizumab was assessed at Day90 according to CHUN criteria.

CONCLUSIONS

Capillary density measured using capillaroscopy is not a good predictor of the early response to bevacizumab-based chemotherapy. (NCT01810744).

摘要

背景

贝伐单抗是一种靶向血管内皮生长因子A（VEGF-A）的重组人源化单克隆免疫球蛋白G1抗体。它目前与化疗联合用于转移性结直肠癌的一线或二线治疗。既往研究表明，抗血管生成药物可降低毛细血管密度。我们评估了毛细血管密度降低与基于贝伐单抗的化疗反应之间的联系。

结果

总体而言，43例接受一线基于贝伐单抗化疗的转移性结直肠癌患者入组。在第90天时，12例患者（27.9%）出现疾病进展。所有患者的毛细血管密度均降低。不同时间点的受试者工作特征（ROC）分析及毛细血管密度变化显示，其对第90天的反应诊断性能较差。

材料与方法

2013年至2015年，在我们法国癌症护理中心接受治疗且符合贝伐单抗联合化疗条件的转移性结直肠癌患者被纳入一项前瞻性单中心研究。在第1天、第15天和第30天使用毛细血管镜评估毛细血管密度。根据CHUN标准在第90天评估对贝伐单抗的反应。

结论

使用毛细血管镜测量的毛细血管密度并非基于贝伐单抗化疗早期反应的良好预测指标。（NCT01810744）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/f2805330d10b/oncotarget-09-12599-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/b1ccfc48c7d5/oncotarget-09-12599-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/b9969d337ba2/oncotarget-09-12599-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/5300021c3fe3/oncotarget-09-12599-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/9cd8b0e8880f/oncotarget-09-12599-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/f2805330d10b/oncotarget-09-12599-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/b1ccfc48c7d5/oncotarget-09-12599-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/b9969d337ba2/oncotarget-09-12599-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/5300021c3fe3/oncotarget-09-12599-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/9cd8b0e8880f/oncotarget-09-12599-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbc8/5849157/f2805330d10b/oncotarget-09-12599-g005.jpg

相似文献

1
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.毛细血管密度作为贝伐单抗治疗转移性结直肠癌疗效的早期生物标志物无价值：一项前瞻性临床试验
Oncotarget. 2017 Dec 1;9(16):12599-12608. doi: 10.18632/oncotarget.22822. eCollection 2018 Feb 27.
2
Anti-angiogenic therapies for metastatic colorectal cancer.转移性结直肠癌的抗血管生成疗法。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD005392. doi: 10.1002/14651858.CD005392.pub3.
3
Integration of novel agents in the treatment of colorectal cancer.新型药物在结直肠癌治疗中的整合应用。
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
4
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.西妥昔单抗（单药或联合化疗）、贝伐珠单抗（联合非奥沙利铂化疗）和帕尼单抗（单药治疗）用于一线化疗后转移性结直肠癌治疗的临床疗效和成本效果评价（技术评估 150 号报告的部分回顾和技术评估 118 号报告的综述）：系统评价和经济模型。
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
5
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.针对内分泌难治性或耐药性转移性乳腺癌的血管内皮生长因子（VEGF）靶向治疗。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008941. doi: 10.1002/14651858.CD008941.pub2.
6
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.EFFORT 研究方案：在不可切除/转移性结直肠癌患者中，FOLFOXIRI 联合贝伐珠单抗治疗进展后或维持治疗期间使用 FOLFIRI 联合阿柏西普二线治疗的前瞻性研究。
BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9.
7
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.贝伐珠单抗联合或不联合厄洛替尼作为转移性结直肠癌（GERCOR DREAM；OPTIMOX3）患者的维持治疗：一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22.
8
Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer.转移性结直肠癌的抗血管生成治疗连续性。
J Gastrointest Oncol. 2013 Sep;4(3):299-307. doi: 10.3978/j.issn.2078-6891.2013.030.
9
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.转移性结直肠癌（mCRC）中抗血管生成治疗的生物标志物：原始数据及文献综述
Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30.
10
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.亚叶酸钙、氟尿嘧啶、奥沙利铂联合贝伐珠单抗与 S-1 和奥沙利铂联合贝伐珠单抗治疗转移性结直肠癌患者（SOFT）：一项开放标签、非劣效性、随机 3 期临床试验。
Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11.

本文引用的文献

1
Colorectal cancer population screening programs worldwide in 2016: An update.2016 年全球结直肠癌人群筛查计划：更新。
World J Gastroenterol. 2017 May 28;23(20):3632-3642. doi: 10.3748/wjg.v23.i20.3632.
2
Better survival in right-sided versus left-sided stage I - III colon cancer patients.右侧与左侧I - III期结肠癌患者的生存情况更佳。
BMC Cancer. 2016 Jul 28;16:554. doi: 10.1186/s12885-016-2412-0.
3
Capillaroscopy - a role in modern rheumatology.毛细血管镜检查——在现代风湿病学中的作用
Reumatologia. 2016;54(2):67-72. doi: 10.5114/reum.2016.60215. Epub 2016 Jun 3.
4
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.新诊断卵巢癌女性使用或不使用贝伐单抗的标准化疗（ICON7）：一项3期随机试验的总生存结果
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
5
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性结直肠癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9. doi: 10.1093/annonc/mdu260. Epub 2014 Sep 4.
6
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.FOLFIRI 联合西妥昔单抗与 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者（FIRE-3）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.
7
The use of bevacizumab in non-small cell lung cancer: an update.贝伐珠单抗在非小细胞肺癌中的应用：最新进展。
Anticancer Res. 2014 Apr;34(4):1537-45.
8
VEGF inhibition, hypertension, and renal toxicity.血管内皮生长因子抑制、高血压和肾毒性。
Curr Oncol Rep. 2012 Aug;14(4):285-94. doi: 10.1007/s11912-012-0242-z.
9
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.贝伐珠单抗联合干扰素 α-2a 治疗转移性肾细胞癌的 III 期临床试验（AVOREN）：总生存的最终分析。
J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5.
10
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.贝伐单抗治疗结直肠癌肝转移患者的计算机断层扫描形态学标准与病理反应及生存的相关性
JAMA. 2009 Dec 2;302(21):2338-44. doi: 10.1001/jama.2009.1755.